NCT07161973

Brief Summary

Diminished use of skeletal muscle, such as occurs with many chronic diseases (e.g., heart failure or cancer cachexia), denervation, bedrest, immobilization (e.g., limb casting or bracing), etc., is a common clinical condition affecting untold millions of individuals each year. Such disuse leads to a rapid decline in muscle fiber area and hence whole muscle size, contributing to a decrease in strength, speed, and power as well as alterations in energy metabolism. Collectively, these changes lead to reduced physical function and contribute to the seriousness of any disease, illness (e.g., pneumonia), surgery (e.g., joint replacement), or injury (e.g., broken bone) accompanied by decreased muscular activity. Currently, there are no effective pharmacological treatments to prevent disuse-associated muscle wasting in humans. The above-described effects of disuse appear to be due, at least in part, to a decrease in nitric oxide (NO) bioavailability. Reduced synthesis of NO and/or increased NO destruction (due to increased production of oxygen free radicals) likely contributes to the mitochondrial changes, energetic abnormalities, and muscle atrophy resulting from immobilization. The objective of this study is to investigate the potential benefits of dietary nitrate supplementation on immobilization-induced changes in muscle contractile function and mitochondrial respiratory capacity in young healthy men. Our disuse-induced muscle atrophy model will involve wearing a knee brace for a period of 14 d.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
8mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress29%
Jan 2026Dec 2026

First Submitted

Initial submission to the registry

August 8, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

September 9, 2025

Completed
5 months until next milestone

Study Start

First participant enrolled

January 30, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2026

Last Updated

February 23, 2026

Status Verified

February 1, 2026

Enrollment Period

11 months

First QC Date

August 8, 2025

Last Update Submit

February 20, 2026

Conditions

Keywords

Dietary NitrateImmobilization

Outcome Measures

Primary Outcomes (1)

  • Muscle mitochondrial function

    Muscle mitochondrial respiratory capacity assessed in vitro using high resolution respirometry and in vivo using a near infrared spectroscopy/occlusion protocol

    14 days

Secondary Outcomes (3)

  • Muscle strength

    14 days

  • Muscle speed

    14 days

  • Muscle power

    14 days

Study Arms (2)

Nitrate

EXPERIMENTAL

Nitrate-rich beetroot juice

Dietary Supplement: Beetroot Juice - Active

Placebo

PLACEBO COMPARATOR

Nitrate-free beetroot juice

Dietary Supplement: Placebo Beetroot Juice Without Nitrate

Interventions

Beetroot Juice - ActiveDIETARY_SUPPLEMENT

Nitrate-rich beetroot juice

Nitrate

Nitrate-free beetroot juice

Placebo

Eligibility Criteria

Age18 Years - 44 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Men age 18-44
  • Above the minimum threshold of the IPAQ questionnaire
  • Below the maximum threshold of the IPAQ questionnaire

You may not qualify if:

  • Men and women \<18 or \>44 years of age
  • Unable to provide informed consent
  • Known clotting disorder
  • Previous history of deep vein thrombosis
  • Injury to either leg resulting in reduced mobility in the previous year
  • Currently dieting or weight instability for the past 3 months
  • Epileptic
  • Pacemaker or other implantable heart device
  • Currently taking antibiotics
  • Current smoker
  • Stage II hypertension (resting blood pressure \>140/\>90)
  • Previously undergone a revascularization procedure involving a vascular graft or stenting of the femoral or popliteal arteries
  • Those taking phosphodiesterase inhibitors (e.g., Viagra), proton pump inhibitors, antacids, xanthine oxidase inhibitors, hormonal contraceptives or on hormone replacement therapy
  • If participant's doctor has ever said that he/she has a heart condition and that he/she should only do physical activity recommended by a doctor
  • Pain in chest when doing physical activity
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Indiana University Indianapolis

Indianapolis, Indiana, 46202, United States

RECRUITING

MeSH Terms

Conditions

Muscular Disorders, Atrophic

Interventions

Nitrates

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesNeuromuscular DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

AnionsIonsElectrolytesInorganic ChemicalsNitric AcidNitrogen CompoundsOrganic Chemicals

Study Officials

  • Andrew R Coggan, PhD

    Indiana University Indianapolis

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Andrew R Coggan, PhD

CONTACT

William S Zoughaib, BS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

August 8, 2025

First Posted

September 9, 2025

Study Start

January 30, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Last Updated

February 23, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

All non-PHI individual participant data will be shared upon reasonable request.

Time Frame
Data will be made available upon completion of the study and publication of the final results.

Locations